A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)
Status:
Completed
Trial end date:
2010-02-17
Target enrollment:
Participant gender:
Summary
A study to evaluate the response of growth factor signatures (GFS) to a single dose of
dalotuzumab in participants with triple negative (TN) or estrogen receptor (ER)-positive
luminal B breast cancer. The primary hypothesis is that dalotuzumab will induce a decrease in
the GFS in at least 40% of participants.